Ryo Nishikawa

17.7k total citations · 3 hit papers
201 papers, 8.4k citations indexed

About

Ryo Nishikawa is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ryo Nishikawa has authored 201 papers receiving a total of 8.4k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Genetics, 56 papers in Pulmonary and Respiratory Medicine and 46 papers in Molecular Biology. Recurrent topics in Ryo Nishikawa's work include Glioma Diagnosis and Treatment (124 papers), Brain Metastases and Treatment (42 papers) and Radiomics and Machine Learning in Medical Imaging (23 papers). Ryo Nishikawa is often cited by papers focused on Glioma Diagnosis and Treatment (124 papers), Brain Metastases and Treatment (42 papers) and Radiomics and Machine Learning in Medical Imaging (23 papers). Ryo Nishikawa collaborates with scholars based in Japan, United States and United Kingdom. Ryo Nishikawa's co-authors include Wolfgang Wick, Webster K. Cavenee, Warren Mason, Olivier Chinot, Roger Henriksson, Frank Saran, Timothy F. Cloughesy, Masao Matsutani, Gordon N. Gill and Xiang-Dong Ji and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Ryo Nishikawa

183 papers receiving 8.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

2014 1.8k citations Olivier Chinot, Wolfgang Wick et al. profile →
Glioma

2015 792 citations Michael Weller, Wolfgang Wick et al. Nature Reviews Disease Primers profile →
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.

1994 748 citations Ryo Nishikawa, Webster K. Cavenee et al. profile →

Peers

Countries citing papers authored by Ryo Nishikawa

Since Specialization

Citations

This map shows the geographic impact of Ryo Nishikawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryo Nishikawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryo Nishikawa more than expected).

Fields of papers citing papers by Ryo Nishikawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryo Nishikawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryo Nishikawa. The network helps show where Ryo Nishikawa may publish in the future.

Co-authorship network of co-authors of Ryo Nishikawa

This figure shows the co-authorship network connecting the top 25 collaborators of Ryo Nishikawa. A scholar is included among the top collaborators of Ryo Nishikawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryo Nishikawa. Ryo Nishikawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment of Unruptured Large and Giant Paraclinoid Aneurysms in Japan at the Time of Flow Diverter Introduction: A Nationwide, Multicenter Survey by the Japanese Society on Surgery for Cerebral Stroke 2025 ·World Neurosurgery ·Kazuya Kanemaru, Hideyuki Yoshioka, (unknown), (unknown), Hajime Arai, Miki Fujimura, Kensuke Suzuki, (unknown), Nurçin Saka, Ryo Nishikawa, Yuichi Murayama, Jun Takahashi, Tooru Inoue, (unknown), (unknown), Hiroyuki Kinouchi	0
2	Using artificial intelligence to improve human performance: efficient retinal disease detection training with synthetic images 2024 ·British Journal of Ophthalmology ·Hitoshi Tabuchi, (unknown), (unknown), Ryo Nishikawa, Toshihiko Nagasawa, Tomofusa Yamauchi, Mao Tanabe, (unknown), (unknown), Yasuyuki Nakae, Yoshiaki Kiuchi, Miguel O. Bernabéu	10
3	Nasal immature teratoma in an elderly patient: Clinicopathological and epigenetic analogies with central nervous system counterparts, alongside genomic divergences 2024 ·Neuropathology ·Shintaro Inoue, (unknown), Shota Tanaka, Masashi Nomura, Shunsaku Takayanagi, Yuki Saito, Shu Kikuta, Kenji Kondo, Reiko Matsuura, Masako Ikemura, (unknown), Masao Matsutani, Ryo Nishikawa, Yuko Matsushita, (unknown), (unknown)	0
4	Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma 2024 ·Neuro-Oncology Advances ·Hajime Yonezawa, Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima, Yasuhito Terui, Yoshiki Arakawa, Katsunori Asai, Noriko Fukuhara, Kazuhiko Sugiyama, Naoki Shinojima, (unknown), Ryo Nishikawa	11
5	Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG08.02) randomized clinical trial 2021 ·Neuro-Oncology Advances ·Andrew Song, Keyue Ding, Iyad Alnahhas, Normand Laperrière, James Perry, Warren Mason, Chad Winch, Chris J. O’Callaghan, Johan Menten, Alba A. Brandes, Claire Phillips, Michael Fay, Ryo Nishikawa, David Osoba, J. Gregory Cairncross, Wilson Roa, Wolfgang Wick, Wenyin Shi	12
6	Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients 2020 ·Journal of Neuro-Oncology ·(unknown), Alba A. Brandes, J. Gregory Cairncross, Keyue Ding, Michael Fay, Normand Laperrière, Johan Menten, Ryo Nishikawa, Christopher J. O’Callaghan, James Perry, Claire Phillips, Wilson Roa, Wolfgang Wick, Chad Winch, Warren Mason	17
7	Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer 2016 ·Clinical Cancer Research ·Julie George, Motonobu Saito, Koji Tsuta, Reika Iwakawa, Kouya Shiraishi, Andreas H. Scheel, (unknown), Shun‐ichi Watanabe, Ryo Nishikawa, Masayuki Noguchi, Martin Peifer, Se Jin Jang, Iver Petersen, Reinhard Büttner, Curtis C. Harris, Jun Yokota, Roman K. Thomas, Takashi Kohno	93
8	Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma 2016 ·Neuro-Oncology ·Wolfgang Wick, Olivier Chinot, Martin Bendszus, Warren Mason, Roger Henriksson, Frank Saran, Ryo Nishikawa, Cédric Révil, Yannick Kerloëguen, Timothy F. Cloughesy	68
9	A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways 2016 ·Nature Communications ·Tianzhi Huang, Angel A. Alvarez, Rajendra P. Pangeni, Craig Horbinski, Songjian Lu, Sung-Hak Kim, C. David James, Jeffery J. Raizer, John A. Kessler, (unknown), Erik P. Sulman, Gaetano Finocchiaro, Ming Tan, Ryo Nishikawa, Xinghua Lu, Ichiro Nakano, Bo Hu, Shi-Yuan Cheng	75
10	146P Tolerability and pharmacokinetics (PK) of ABT-414 in Japanese patients (pts) with recurrent malignant glioma 2016 ·Annals of Oncology ·Yusuke Narita, Motoo Nagane, Naoki Kagawa, Kazuhiko Mishima, Tetsuya Yamamoto, Toshihiko Wakabayashi, Takashi Hamada, (unknown), (unknown), (unknown), Xiong, Clara B. Ocampo, Ryo Nishikawa	1
11	STUDY ABOUT THE INFLUENCE TOWARD LOCAL BY “HISTORICAL ROUTES POLICY” OF CULTURAL AFFAIRS AGENCY<br>Focus on the initial actions between the 1970s and the early 1980s 2015 ·Journal of Architecture and Planning (Transactions of AIJ) ·Ryo Nishikawa, Yukio Nishimura, Aya Kubota	0
12	Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial 2015 ·Journal of Clinical Oncology ·Thomas Sandmann, Richard Bourgon, Josep Garcia, Congfen Li, Timothy F. Cloughesy, Olivier Chinot, Wolfgang Wick, Ryo Nishikawa, Warren Mason, Roger Henriksson, Frank Saran, Albert Lai, N. Moore, Samir Kharbanda, Franklin Peale, Priti S. Hegde, Lauren E. Abrey, Heidi Phillips, Carlos Bais	208
13	Glioma breakdown → 2015 ·Nature Reviews Disease Primers ·Michael Weller, Wolfgang Wick, Ken Aldape, Michael Brada, Mitchel S. Berger, Stefan M. Pfister, Ryo Nishikawa, Mark Rosenthal, Patrick Y. Wen, Roger Stupp, Guido Reifenberger	792
14	Impact of Late Effects on Health-Related Quality of Life in Survivors of Pediatric Brain Tumors 2014 ·Cancer Nursing ·Iori Sato, Akiko Higuchi, Takaaki Yanagisawa, (unknown), Toshihiro Kumabe, Kazuhiko Sugiyama, Akitake Mukasa, Nobuhito Saito, Yutaka Sawamura, Mizuhiko Terasaki, Soichiro Shibui, Jun Takahashi, Ryo Nishikawa, Yasushi Ishida, Kiyoko Kamibeppu	22
15	Overview of Arterial Thromboembolic Events (ATEs) in AVAglio, a Randomized, Placebo-controlled Phase III Trial of Bevacizumab, Radiotherapy and Temozolomide (BEV+RT/TMZ) for Newly Diagnosed Glioblastoma (S22.003) 2014 ·Neurology ·Warren Mason, Timothy F. Cloughesy, Wolfgang Wick, Roger Henriksson, Frank Saran, Ryo Nishikawa, (unknown), Cédric Révil, Josep Garcia, Olivier Chinot	1
16	HEALTH-RELATED QUALITY OF LIFE (HRQOL) ANALYSES IN THE AVAGLIO STUDY, A RANDOMIZED, PLACEBO-CONTROLLED PHASE III TRIAL OF BEVACIZUMAB, TEMOZOLOMIDE AND RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA 2013 ·Neuro-Oncology ·Martin Klein, Roger Henriksson, Andrew Bottomley, Timothy F. Cloughesy, Wolfgang Wick, Warren Mason, Frank Saran, Ryo Nishikawa, Arliene Ravelo, Magalie Hilton, Olivier Chinot	4
17	FINAL EFFICACY AND SAFETY RESULTS FROM AVAglio, A PHASE III TRIAL OF BEVACIZUMAB (BEV) PLUS TEMOZOLOMIDE (TMZ) ANDRADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA 2013 ·Neuro-Oncology ·Olivier Chinot, Wolfgang Wick, Warren Mason, Roger Henriksson, Frank Saran, Ryo Nishikawa, Alain Carpentier, Khê Hoang‐Xuan, Petr Kavan, Dana Cernea, Alba A. Brandes, Magalie Hilton, Yannick Kerloëguen, (unknown), (unknown)	3
18	A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme 2010 ·Neuro-Oncology ·James Perry, Chris J. O’Callaghan, Keyue Ding, (unknown), Claire Phillips, Johan Menten, Michael Fay, Ryo Nishikawa, Chad Winch, Normand Laperrière	16
19	ELMO1 and Dock180, a Bipartite Rac1 Guanine Nucleotide Exchange Factor, Promote Human Glioma Cell Invasion 2007 ·Cancer Research ·Michael J. Jarzynka, Bo Hu, (unknown), Ifat Bar-Joseph, (unknown), Takanori Hirose, Lisa B. Haney, Kodi S. Ravichandran, Ryo Nishikawa, Shi‐Yuan Cheng	112
20	Expression of vascular endothelial growth factor in human brain tumors 1998 ·Acta Neuropathologica ·Ryo Nishikawa, Shi‐Yuan Cheng, (unknown), Hui Huang, Webster K. Cavenee, Masao Matsutani	84

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact